Myocardial Infarction News and Research

RSS

Boston Scientific reports positive data from PLATINUM Element Stent quantitative coronary angiography study

Boston Scientific Corporation today announced data from its PLATINUM QCA study, which is designed to evaluate the Company's PROMUS Element™ Everolimus-Eluting Platinum Chromium Coronary Stent. The results provided 30-day and nine-month clinical outcomes and nine-month quantitative coronary angiography (QCA) and intravascular ultrasound (IVUS) data supporting the safety and efficacy of the PROMUS Element Stent.

22 Sep 2010

PROMUS Element Stent receives expanded indications approval for high-risk diabetic and AMI patient groups

Boston Scientific Corporation today announced that its PROMUS® Element™ Everolimus-Eluting Coronary Stent System has received CE Mark approval for use in patients with diabetes and those experiencing an acute myocardial infarction (AMI), or heart attack.

21 Sep 2010

Celera receives patent on KIF6 gene variant

Celera Corporation today announced that the United States Patent and Trademark Office has issued United States Patent 7,799,530 relating to methods of determining heart attack risk by detecting the KIF6 gene variant and reduction of such increased risk by statin therapy.

21 Sep 2010

Paper highlights need for new studies and guidelines around oxygen therapy during MI

The European Society of Cardiology (ESC) welcomes a paper published today in the Journal of the American College of Cardiology (JACC )(1) highlighting concerns over the use of oxygen therapy during MI in patients with normal oxygen levels. The publication adds to calls for revision of the STEMI guidelines around oxygen therapy and for a prospective, large scale randomised trials, issues that were both first raised in a Cochrane Review published in June.

21 Sep 2010

AB5000 VADs can restore normal hemodynamics in AMI cardiogenic shock patients: Report

Results from the U.S. registry of Abiomed, Inc. AB5000 patients were recently published in the September 2010 issue of The Annals of Thoracic Surgery. The paper, "Use of the AB5000TM Ventricular Assist Device in Cardiogenic Shock After Acute Myocardial Infarction (AMI)," concludes that the "results from this nationwide registry suggest that VADs can restore normal hemodynamics and support recovery of native cardiac function in the majority of survivors when conventional therapies fail."

21 Sep 2010

NQF endorses 8 outcome measures for pulmonary, cardiovascular conditions and care provided in ICU

To improve healthcare quality and give patients and providers more information about the results of care, the National Quality Forum (NQF) has endorsed eight outcome measures for pulmonary and cardiovascular conditions and care provided in the intensive care unit (ICU). This is the first in a set of patient outcome measures NQF is reviewing.

20 Sep 2010

Elixir Medical commences enrollment in EXCELLA BD trial for DESyne BD Novolimus Eluting CSS

Elixir Medical Corporation, a developer of product platforms that combine innovative medical devices with potent pharmaceuticals for site-specific therapies, announced the initiation of patient enrollment in the EXCELLA BD Randomized Clinical Trial designed to evaluate Elixir's next generation Novolimus Eluting Coronary Stent System (CSS) with bioabsorbable coating, the Elixir DESyne BD Novolimus Eluting CSS.

18 Sep 2010

Abbott to present two drug eluting stents data at TCT symposium

Abbott today announced the company's schedule of key data presentations at the Cardiovascular Research Foundation's 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C., to be held Sept. 21 – 25.

17 Sep 2010

Study finds GRK2 molecule promotes cell death after heart attack

A molecule known to be involved in progressive heart failure has now been shown to also lead to permanent damage after a heart attack, according to researchers at Thomas Jefferson University.

16 Sep 2010

Bone marrow-derived mononuclear cell therapy benefits patients after severe heart attack

The first randomized, placebo-controlled U.S. clinical trial to assess the use of bone marrow-derived mononuclear cells (BMC) in patients after a ST-elevation myocardial infarction (STEMI; severe heart attack) demonstrated a strong safety profile for this cell therapy, based on phase 1 results published in the September issue of the American Heart Journal.

15 Sep 2010

World Congress on Arthrosis to take place in Belgium from September 23 to 26, 2010

Over a 1000 experts from the world will participate in the Osteoarthritis Research Society International (OARSI) congress, under the Presidency of the Belgian Professor Yves Henrotin (University of Liège).

14 Sep 2010

Emergency physicians to present research studies at Research Forum 2010

The risks associated with boarding admitted patients in the emergency department – including patient mortality – as well as proposed solutions will be key themes of Scientific Assembly, the annual meeting of the American College of Emergency Physicians. In addition, emergency physicians will present more than 450 research studies during 2010 Research Forum, the premier, annual scientific research event focused on the latest advances in the practice of emergency medicine.

14 Sep 2010

Amorcyte receives patent for chemotactic hematopoietic stem cell product

Amorcyte, Inc., a biopharmaceutical company developing cell therapy products to treat cardiovascular disease, today announced that it has been granted United States Patent number 7,794,705 titled "Compositions and Methods of Vascular Injury Repair." The patent contains both composition of matter and method claims surrounding therapeutic chemotactic hematopoietic stem cell products used in treating or repairing a vascular injury following an acute myocardial infarction (AMI), and delivery of the cell therapy.

13 Sep 2010

NewCardio publishes Cardio3KG clinical study for acute cardiac diagnosis

NewCardio a cardiac diagnostic technology provider, announced today that a clinical study of the Cardio3KG in acute cardiac diagnosis has been published in the August 2010 issue of the peer-reviewed journal, Heart Rhythm, the official journal of the Heart Rhythm Society.

9 Sep 2010

Researchers to study protein fragments released into bloodstream after heart attack

A blood test to diagnose which heart attack survivors will suffer heart failure is the goal of a new five-year, $11.6 million contract to the UT Health Science Center San Antonio from the National Heart, Lung, and Blood Institute (NHLBI).

4 Sep 2010

Data from ESC confirms reduction in adverse events with CYPHER Stent

Additional Analysis of 18 Month Data of the SORT OUT III Trial Provides Detail on Safety and Efficacy Outcomes in Patients With Diabetes, Acute Coronary Syndrome, or Treatment of Multiple Lesions

3 Sep 2010

Iroko Cardio International Sàrl announces data on HDB dosing of tirofiban, abciximab in interventional cardiology

Iroko Cardio International Sàrl announces long-term, three-year, mortality data from the Phase III, open label, multi-national study comparing high-dose bolus (HDB) dosing of AGGRASTAT(tirofiban) (25mcg/kg bolus followed by a 0.15mcg/kg/min infusion for 18-24 hours) vs. ReoPro (abciximab) in patients undergoing primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI), presented at the 2010 European Society of Cardiology Meeting in Stockholm, Sweden.

3 Sep 2010

InfraReDx receives 510(k) clearance to market LipiScan IVUS Coronary Imaging System

InfraReDx, Inc., a medical device company developing intelligent cardiovascular diagnostic imaging technologies, today announced that it has received 510(k) clearance from the United States Food and Drug Administration to market the LipiScan IVUS Coronary Imaging System. LipiScan IVUS is the first cardiac catheter to combine intravascular ultrasound and near-infrared spectroscopy to help cardiologists identify and characterize the plaques that complicate stenting and are associated with acute coronary events.

2 Sep 2010

Lack of preparation for winter sports, high altitudes and low temperatures trigger acute myocardial infarction

A study carried out by cardiologists from the Medical University of Innsbruck has investigated the risk of myocardial infarction (heart attack) amongst winter sports tourists to the Tyrolean Alps. The research shows that inadequate preparation for the intense physical exertion required, combined with the effects of altitude and low temperature, leads to an increase in heart attack incidents, particularly during the first two days of vacation.

2 Sep 2010

ESC releases new Clinical Practice Guidelines covering Myocardial Revascularisation

The European Society of Cardiology (ESC) today announces the release of new Clinical Practice Guidelines covering Myocardial Revascularisation. These guidelines were developed following pioneering and extensive co-operation between the ESC and the European Association of Cardio-Thoracic Surgeons (EACTS).

2 Sep 2010

Myocardial Infarction News and Research

Boston Scientific reports positive data from PLATINUM Element Stent quantitative coronary angiography study

PROMUS Element Stent receives expanded indications approval for high-risk diabetic and AMI patient groups

Celera receives patent on KIF6 gene variant

Paper highlights need for new studies and guidelines around oxygen therapy during MI

AB5000 VADs can restore normal hemodynamics in AMI cardiogenic shock patients: Report

NQF endorses 8 outcome measures for pulmonary, cardiovascular conditions and care provided in ICU

Elixir Medical commences enrollment in EXCELLA BD trial for DESyne BD Novolimus Eluting CSS

Abbott to present two drug eluting stents data at TCT symposium

Study finds GRK2 molecule promotes cell death after heart attack

Bone marrow-derived mononuclear cell therapy benefits patients after severe heart attack

World Congress on Arthrosis to take place in Belgium from September 23 to 26, 2010

Emergency physicians to present research studies at Research Forum 2010

Amorcyte receives patent for chemotactic hematopoietic stem cell product

NewCardio publishes Cardio3KG clinical study for acute cardiac diagnosis

Researchers to study protein fragments released into bloodstream after heart attack

Data from ESC confirms reduction in adverse events with CYPHER Stent

Iroko Cardio International Sàrl announces data on HDB dosing of tirofiban, abciximab in interventional cardiology

InfraReDx receives 510(k) clearance to market LipiScan IVUS Coronary Imaging System

Lack of preparation for winter sports, high altitudes and low temperatures trigger acute myocardial infarction

ESC releases new Clinical Practice Guidelines covering Myocardial Revascularisation

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News